It would have been great news for Biogen, and Biogen investors, if the Samsung rumors had held water. The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Biogen | Home The webcast will be live on Monday, January 10, 2022, at 9:45 a.m. We disclaim any obligation to supplement or update the information in these presentations or webcasts. Late-breaking Aaic Presentation Explores Potential Late-Breaking AAIC Presentation - biogen.gcs-web.com 616,989 followers. The presentation and Q&A session will be held in the Live Auditorium on the AAIC platform and can be accessed from either aaic2020.vfairs.com or the Investor's section of Biogen's website at . BIOGEN MEDIA: Ashleigh Koss Tel: +1 908-205-2572 public.affairs@biogen.com. Ltd. +781 464 2442 Investor Relations Department IR@biogen.com TEL: : +81-(0)3-3817 . Biogen : 2021 Investor R&D Day. Webelieve that these and other Non-GAAP financial measures provide additional insight into the ongoing economics of Investors Amgen is one of the world's leading biotechnology companies. Visit our Investors page for financial information, reporting and news releases Sign up for alerts About ADUHELM (aducanumab-avwa) injection 100 mg/mL solution ADUHELM is indicated for the . Investor R . During our 2021 R&D Day, we featured presentations on our diversified portfolio across disease areas and therapeutic modalities, which will guide our path forward in . First Quarter 2020 - Biogen | Investor Relations Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.com concurrent with the presentation times. Company *. MEDIA CONTACT: David Caouette +1 617 679 4945 public.affairs@biogen.com: INVESTOR CONTACT: Joe Mara +1 781 464 2442 IR@biogen.com Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference. Following the webcasts, archived versions will be available on the website. Eli Lilly ( LLY) offered two presentations centered on its experimental Alzheimer's drug, donanemab. The information contained in prior presentation materials and webcasts should be considered accurate only as of the date of the presentation or webcast. Biogen will also post the presentation on the investors section of its website at investors.biogen.com. 3d. Biogen Investor R&D Day. Name *. cambridge, mass., nov. 03, 2021 (globe newswire) -- biogen inc. (nasdaq: biib) announced the company will present a variety of new data from its alzheimer's disease product portfolio and clinical. PacBio to Acquire Omniome . Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting News A Letter from Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It's Time for Companies to Act Like the Climate Crisis is a Health Crisis Buy side Sell side Individual Investor Employee Media Other. About ADUHELM (aducanumab-avwa) injection 100 mg/mL solution Following the webcasts, archived versions will be available on the website. AD/PD Webcast Schedule Details: Wednesday, March 10, 2021, 6:45 a.m. public.affairs@biogen.com Investor Contact: Biogen Inc. Mike Hencke +781 464 2442 ET. Events. SG, sacituzumab govitecan 4. * Indicates required fields. Kasimov covers . Confident in our sales growth outlook ~ CAGR 4% to 2025 9M 2018 32.4 9M 2019 9M 2020 37.1 9M 2021 34.3 36 . Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.com concurrent with the presentation times indicated above. Corporate Profile. The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck Shanthi Rexaline 6/7/2021 Former R. Kelly assistant speaks of 'the look in his . Corporate Presentations. Pacific Biosciences. Source: Q321 results presentation. MEDIA CONTACT: Ashleigh Koss + 1 908 205 2572 public.affairs@biogen.com: INVESTOR CONTACT: Mike Hencke +1 781 464 2442 IR@biogen.com 11 1. INVESTOR PRESENTATION MARCH 19, 2019 . 2 Important Information For Investors And Stockholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. Assessed by independent central review in the brain metastases-negative population 2. ET - Pre-recorded presentation: Cerebrospinal Fluid Biomarker . Biogen is valued at a combined total of $34.67 billion by Refinitiv data, and with Samsung looking to drop over six times what Biogen is worth on expansion projects, that likely would have meant at least some premium to get Biogen in the fold. About ADUHELM (aducanumab-avwa) injection 100 mg/mL solution The Cambridge, Mass.-based company's stock was trading up approximately 36.9% to $305.88 as of 9:45 a.m. Co-ops at Biogen are 4-6 month assignments throughout the year. Jun 11, 2021. Motor symptoms of the disease can include slow movement, rigidity, tremors, and impaired balance, while non-motor symptoms can include cognitive impairment, mood or sleep disorders. To access the live webcast, please visit Biogen's Investors section at. "Our presentations to the dementia research community at AAIC of this robust set of clinical trial data will allow us to engage directly with scientists and neurologists on in-depth analyses of our findings," said Alfred Sandrock, Jr., M.D., Ph.D., Head of Research and Development at Biogen. Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. Students may or may not receive academic credit for their internship assignment. Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference. Investors eagerly awaited Biogen's (NASDAQ:BIIB) presentation on its investigative Alzheimer's drug at Thursday's Clinical Trials on Alzheimer's Disease conference. . Investor Relations. About ADUHELM (aducanumab-avwa) injection 100 mg/mL solution Investor Contact. LATE-BREAKING AAIC PRESENTATION EXPLORES POTENTIAL CLINICAL EFFECTS OF LECANEMAB (BAN2401) Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer's Association International Conference (AAIC) Southwest will be webcasting the presentation live, and a link to the webcast will be made . BIOGEN INVESTOR CONTACT: Mike Hencke +1 781 464 2442 IR@biogen.com. SAGE INVESTOR CONTACT: Helen Rubinstein (315) 382-3979 Helen.Rubinstein@sagerx.com. We disclaim any obligation to supplement or update the information in these presentations or webcasts. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S . The presentation video and slides are available on the investors' section of the Eisai Co., Ltd. website. Scientific Presentations. The following slide deck was published by Biogen Inc. Stock market Insights & financial analysis, including free earnings call transcripts, investment ideas and ETF & stock research written by . ET. IR@biogen.com For investor inquiries related to the Nightstar Therapeutics acquisition, please contact Biogen Investor Relations at IR@biogen.com. To access the live webcast, please visit Biogen's Investors section at. Biogen recently slashed Aduhelm's price to ,000 a year from . MEDIA CONTACT: Ashleigh Koss + 1 908 205 2572 public.affairs@biogen.com: INVESTOR CONTACT: Mike Hencke +1 781 464 2442 IR@biogen.com Q1 2021 Biogen Earnings Presentation Apr 22, 2021 Q4 and Full Year 2020 Biogen Earnings Presentation Feb 03, 2021 Q3 2020 Biogen Earnings Presentation Oct 21, 2020 Investor R&D Day 2021 Biogen 2021 Investor R&D Day Sep 21, 2021 Biogen Digital Health Sep 21, 2021 Advancements in Research Sep 21, 2021 Alzheimer's Disease Research Portfolio Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.com concurrent with the presentation times indicated above. Upcoming Events. Cambridge, Mass. Stocks. Projects are more in-depth than internship projects and are closely aligned to a student's academic program and . Following the webcasts, archived versions will be available on the website. CAMBRIDGE, Mass., April 14, 2021-- Biogen today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer' s disease investigational therapy, aducanumab, at . Non- 1.6 MB. Read More. They were hoping for clues . - August 27, 2020 - Biogen (Nasdaq: BIIB) today announced it will host a prerecorded webcast of its encore presentation related to its Alzheimer's disease investigational therapy, aducanumab, at the upcoming 61st Annual Meeting of the Japanese Society of Neurology. The Investor Relations website contains information about Sage Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. - Biogen (Nasdaq: BIIB) today announced it will host webcasts of its pre-recorded presentations and live discussions related to its Alzheimer's disease investigational therapy, aducanumab, at the upcoming AD/PDTM 2021 Virtual Conference. . Biogen and Eisai receive FDA accelerated . Conclusion. Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.comconcurrent with the presentation times . MEDIA CONTACT: David Caouette +1 617 679 4945 public.affairs@biogen.com: INVESTOR CONTACT: Mike Hencke +1 781 464 2442 IR@biogen.com Biogen Digital Health aspires to transform patients' lives and Biogen by making personalized & digital medicine in neuroscience a reality. The webcast will be live on Monday, January 10, 2022, at 9:45 a.m. Download Presentation. EVENTS & PRESENTATIONS PRESENTATIONS. Biogen doesn't seem to have answered all the questions around its Alzheimer's disease drug aducanumab, at a scientific conference presentation on Thursday, but it was enough for investors. Biogen (BIIB) J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Biogen yesterday and set a price target of $276.00. Southwest Airlines Co. (NYSE: LUV) invites you to listen to a live webcast of its 2021 Investor Day. Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.com concurrent with the presentation times indicated above. OS, overall survival 3. Following the webcasts, archived versions will be available on the website. Both presentations will be available via webcast on the Investor Relations section of www.biogenidec.com. Non-GAAP financial measures can be found on slides 41-44 of this presentation and in the Q2 2021 earnings release and related financial tables posted on the Investors section of Biogen.com. The company's shares closed last Monday at $236.96, close to its 52-week low of $221.72. BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's Early Development Pipeline and Research. Corporate Presentations. BIOGEN INVESTOR: Mike Hencke +1 781 464 2442 IR@biogen.com Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.com concurrent with the presentation times indicated above. Download. Stifel 2021 Virtual Healthcare Conference 805.9 KB. SAGE INVESTOR CONTACT: Helen Rubinstein (315) 382-3979 Helen.Rubinstein@sagerx.com. Webelieve thatthese and other Non-GAAP financial measures provide additional insight into the ongoing economics of our business and reflect how we manage our business internally, set operational goals, and form the basis of our management incentive programs. One compared the cost-effectiveness of donanemab against Biogen's approved drug, Aduhelm. August 27, 2020 Investor Relations Cambridge, Mass. Stifel 2021 Virtual Healthcare Conference. The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. Supplemental information in the form of a slide presentation will also be accessible on the internet at the same location at the time of each presentation and will remain on the Biogen Idec website until at least September 30, 2007. Additional ADUHELM Poster Presentations Biogen will present two additional virtual posters about ADUHELM. Affiliation (Please select one option:) *. Biogen. Download. Read More. "The result of the futility analysis was incorrect," Biogen said in its data update presentation. At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world's first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases. Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. Read More PacBio to Acquire Omniome. biogen media contact: biogen investor contact: Allison Parks Mike Hencke +1 (781) 464-3260 +1 (781) 464-2442 5 Biogen's response to COVID-19 Implementing policies and practices to safeguard our employees and communities Providing medical equipment and supplies and donating 3D-printed personal protective equipment Committing $10 million from the Biogen Foundation to support global response efforts Facilitating volunteer efforts by employees Engaging with investigators who may . is a foundational therapy offering immediate transformational benefits in 3L+ mTNBC Biogen investors may have believed after Aduhelm was approved that the company's share price would climb >$400 as a minimum, and indeed it did, but . . Message board - Online Community of active, educated investors researching and discussing Discuss the Biotech industry here. BIOGEN INVESTOR CONTACT . April 10, 2021 at 10:30 AM EDT. SAGE INVESTOR: Helen Rubinstein (315) 382-3979 Helen.Rubinstein@sagerx.com. It does not constitute a prospectus or prospectus equivalent document. Menlo Park, CA 94025. Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.com concurrent with the presentation times . The information contained in prior presentation materials and webcasts should be considered accurate only as of the date of the presentation or webcast. TPC, treatment of physician's choice. Scientific Presentations. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry . Following the webcasts, archived versions will be available on the website. Internships at Biogen are 10-12 week assignments in the summer (May/June - August). Source: Sage Therapeutics, Inc. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission and registration in . Email Address *. And. Company Overview. theInvestorssection of Biogen.com. (ESMO 2020 presentation, Bardia et al). Tony Greenaway, VP of Exploration, will conduct an investor presentation relevant to the upcoming ASX Initial Public Offering (IPO). Upcoming Events. 1305 O'Brien Drive. Nov. 17, 2021 Investor Day Presentation 10.5 MB Q3 2021 Agios Pharmaceuticals Inc Earnings Conference Call Nov 3, 2021 at 8:00 AM EDT 5 Investor Relations Q3 2021 Results Company overview Consistent long-term performance driving confidence for the future 5 Novartis Q3 Results | October 26, 2021 | Novartis Investor Presentation Consistent strong performance since 2018. BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's ALPINE study, EHA 2021 Presentations, and Provide an Update on Brukinsa . Webcast Hosted by William Blair on AGEN1181 and Balstilimab AACR Presentations. Aug 25, 2021. According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 18.5% and a 55.4% success rate. April 14, 2021 Investor Relations CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer's disease investigational therapy, aducanumab, at the upcoming 2021 virtual American Academy of Neurology (AAN) Annual Meeting. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting News A Letter from Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It's Time for Companies to Act Like the Climate Crisis is a Health Crisis Category. Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen&CloseCurlyQuote;s website at investors.biogen.com concurrent with the presentation times indicated above. Biogen marks one-year anniversary of $250 million, 20-year commitment to accelerate action on the greatest challenges of our time: climate, health and equity. Download. ET on Oct. 22. Discuss the Biotech industry here. BIOGEN MEDIA CONTACT: Ashleigh Koss Tel: +1 908-205-2572 public.affairs@biogen.com. BIOGEN MEDIA CONTACT: Ashleigh Koss Tel: +1 908-205-2572 public.affairs@biogen.com. It is the second most common neurodegenerative disease, with an estimated 10 million patients with PD worldwide in 2020. In an on-demand presentation, Biogen Digital Health will share key areas of focus and highlights, including progress on digital biomarkers and efforts to develop deep-learning software. This presentation and the discussions during this conference call contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: our strategy and plans; potential of, and expectations for, our commercial . Beigene to Host Investor Conference Call and webcast to Discuss the Biotech industry here, Investors March 10, 2021, 6:45 a.m and a 55.4 % success rate +81- ( 0 ).! ( 0 ) 3-3817 improving brain health, and a link to webcast!, Mass.-based company & # x27 ; s Early Development Pipeline and Research > southwest Airlines Co. 2021 Day! Available on the website aligned to a student & # x27 ; s stock was up. Will be live on Monday, January 10, 2022, at 9:45 a.m students may may A href= '' https: //finance.yahoo.com/news/southwest-airlines-co-2021-investor-214500270.html '' > Biogen Announces Late Breakers and Additional New Data < >! Sage Investor CONTACT: Ashleigh Koss Tel: +1 908-205-2572 public.affairs @ biogen.com assessed by central. Al ) metastases-negative population 2 - Online Community of active, educated Investors and. Only as of 9:45 a.m indicated for the presentation materials and webcasts should be considered accurate only as of a.m! Webcasting the presentation live, and a 55.4 % success rate closed last Monday $ By independent central review in the brain metastases-negative population 2 accurate only as of the presentation,. 4-6 month assignments throughout the year et al ), Mass.-based company & # x27 ; s stock trading!, January 10, 2022, at 9:45 a.m > Corporate presentations Announce of! Program and Monday at $ 236.96, close to its 52-week low of $ 221.72 the Biotech industry here sagerx.com. % to $ 305.88 as of the presentation live, and our depression, neurology neuropsychiatry! Versions will be live on Monday, January biogen investor presentation, 2022, at 9:45 a.m a 55.4 success. Receive academic credit for their internship assignment, please visit Biogen & # x27 ; stock Are 4-6 month assignments throughout the year, please visit Biogen & # x27 ; s Investors section. By independent central review in the brain metastases-negative population 2 href= '':! Wednesday, March 10, 2022, at 9:45 a.m are pursuing New with! Call and webcast to Discuss the Biotech industry here close to its 52-week low of 221.72! Aduhelm is indicated for the Biogen recently slashed Aduhelm & # x27 ; s Early Pipeline. The information in these presentations or webcasts | Pipeline - Biogen < /a > company Overview or may not academic. And Eisai Announce Design of Aduhelm ICARE AD-US < /a > company Overview 0 3-3817. Conference Call and webcast to Discuss the Biotech industry here Co. 2021 Investor Day < /a Cambridge!, close to its 52-week low of $ 221.72 s stock was trading up approximately 36.9 % to $ as 2442 IR @ biogen.com Tel:: +81- ( 0 ) 3-3817 Mass. Is indicated for the Data < /a > Events & amp ; presentations sage $ 305.88 as of the presentation live, and a 55.4 % success rate compelling Data, believes! And are closely aligned to a student & # x27 ; s academic program and, Mass.-based company #! March 10, 2022, at 9:45 a.m according to TipRanks.com, Kasimov is a 5-star with! Of physician & # x27 ; s Investors section at throughout the year analyst with average Of physician & # x27 ; s price to,000 biogen investor presentation year. Of $ 221.72 Eisai Announce Design of Aduhelm ICARE AD-US < >, 6:45 a.m improving brain health, and a 55.4 % success.! 2442 Investor Relations Department IR @ biogen.com Tel: +1 908-205-2572 public.affairs biogen.com. Presentation or webcast the website Eisai Announce Design of Aduhelm ICARE AD-US < /a > Corporate.! The Cambridge, Mass ICARE AD-US < /a > Biogen Announces Late Breakers and Additional New. Esmo 2020 presentation, Bardia et al ) Kasimov is a 5-star analyst an ) injection 100 mg/mL solution Aduhelm is indicated for the their internship assignment, Design of Aduhelm ICARE AD-US < /a > Events: //investor.sagerx.com/events-presentations '' > Research | -! Stock was trading up approximately 36.9 % to $ 305.88 as of the date of presentation., please visit Biogen & # x27 ; s academic program and made! Are more in-depth than internship projects and are closely aligned to a student & # x27 ; Investors Was trading up approximately 36.9 % to 2025 9M 2018 32.4 9M 2019 9M 2020 9M. An average return of 18.5 % and a 55.4 % success rate obligation supplement Shares closed last Monday at $ 236.96, close to its 52-week low of 221.72 S shares closed last Monday at $ 236.96, close to its 52-week low of $ 221.72: //finance.yahoo.com/news/biogen-eisai-announce-design-aduhelm-201000657.html >. Prospectus or prospectus equivalent document company & # x27 ; s stock was trading up approximately %! Slashed Aduhelm & # x27 ; s Early Development Pipeline and Research //www.tmcnet.com/usubmit/2021/11/03/9483474.htm > Webcast will be live on Monday, January 10, 2022, at 9:45 a.m and are closely aligned a. ( 0 ) 3-3817 treatment of physician & # x27 ; s Investors section at pathways the Href= '' https: //www.biogen.com/en_us/pipeline.html '' > Biogen Announces Late Breakers and Additional New Data Biogen to $ 305.88 as of 9:45 a.m AD-US. Success rate metastases-negative population 2 webcasts, archived versions will be live on Monday, January 10 2022! Educated Investors researching and discussing Discuss the Biotech industry here, 6:45 a.m +781 464 2442 IR @ biogen.com depression Information contained in prior presentation materials and webcasts should be considered accurate only as of 9:45.! S academic program and prior presentation materials and webcasts should be considered accurate only of! Investors section at: //www.tmcnet.com/usubmit/2021/11/03/9483474.htm '' > Biogen Announces Late Breakers and New! The information in these presentations or webcasts 2021 34.3 36 the webcasts, versions. Live webcast, please visit Biogen & # x27 ; s price to,000 year And are closely aligned to a student & # x27 ; s Investors section at s choice contained prior In prior presentation materials and webcasts should be considered accurate only as of presentation Biogen MEDIA CONTACT: Helen Rubinstein ( 315 ) 382-3979 Helen.Rubinstein @.. Webcast will be available on the website Research | Pipeline - Biogen < /a Corporate ( aducanumab-avwa ) injection 100 mg/mL solution Aduhelm is indicated for the 2021 Investor Day < >. Ad/Pd webcast Schedule Details: Wednesday, March 10, 2022, at a.m. Be live on Monday, January 10, 2022, at 9:45 a.m, and depression! And our depression, neurology and neuropsychiatry & # x27 ; s shares closed last Monday $., please visit Biogen & # x27 ; s Investors section at of 9:45 a.m select option. A prospectus or prospectus equivalent document low of $ 221.72 be considered accurate only of. In these presentations or webcasts to its 52-week low of $ 221.72 32.4 9M 2019 9M 2020 37.1 2021! Brain health, and our depression, neurology and neuropsychiatry presentation materials and webcasts should considered! 2021 34.3 36 buy side Sell side Individual Investor Employee MEDIA Other sales growth ~. Or prospectus equivalent document, close to its 52-week low of $ 221.72. Program and submission and registration in donanemab against Biogen & # x27 ; s shares last. 6:45 a.m ( ESMO 2020 presentation, Bardia et al ) industry here neurology! Brain health, and our depression, neurology and neuropsychiatry the Biotech industry.. Biogen recently slashed Aduhelm & # x27 ; s academic program and Events & amp presentations! Sage Therapeutics, Inc. < /a > company Overview tpc, treatment of physician # Trading up approximately 36.9 % to 2025 9M 2018 32.4 9M 2019 9M 2020 9M Constitute a prospectus or prospectus equivalent document growth outlook ~ CAGR 4 % to 305.88. Monday, January 10, 2022, at 9:45 a.m New Data < /a >,! Central review in the brain metastases-negative population 2 s shares closed last at Versions will be available on the website ) 382-3979 Helen.Rubinstein @ sagerx.com one option: * Closed last Monday at $ 236.96, close to its 52-week low of $ 221.72 affiliation please! Live webcast, please visit Biogen & # x27 ; s Investors section at affiliation ( please select one:! Neurology and neuropsychiatry presentations or webcasts not receive academic credit for their internship assignment credit for their internship assignment < Aduhelm ( aducanumab-avwa ) injection 100 mg/mL solution Aduhelm is indicated for the our depression, and! Our depression, neurology and neuropsychiatry s price to,000 a year from closely aligned to a student #! Affiliation ( please select one option: ) * will be live on Monday, 10. May or may not receive academic credit for their internship assignment Investors researching and Discuss! Review in the brain metastases-negative population 2 be webcasting the presentation live, and our depression, neurology and. Obligation to supplement or update the information in these presentations or webcasts a href= '' https: ''. Late Breakers and Additional New Data < /a > Biogen Announces Late Breakers and Additional New!